Pricing Log in Create free account
Friday 6 November 2026 Export BEAM’s income statement to Excel — free account

Beam Therapeutics Inc.

BEAM Healthcare Biotechnology

Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.

Revenue
−96.8%
EPS
−16.7%
Free cash flow
−29.5%

Quarter to September 2026, against a year earlier

26.35 0.48 +1.86%
Market cap
$2.7B
P/E
0.0×
Fwd P/E
−6.2×
Dividend yield
—
F-score
4/9
Altman Z
5.41
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Beam Therapeutics Inc. (BEAM) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Beam Therapeutics Inc. (BEAM) trades at a EV/Sales of 12.2×. Over the past ten years it has ranged from 0.0× (March 2020) to 326,375× (July 2021); the current reading is higher than 32% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 11.9× (44.26%)
FY2024 21.3× 640.20%
FY2023 2.9× (89.73%)
FY2022 28.0× (66.19%)
FY2021 82.8× (99.95%)
FY2020 150,693× —
FY2019 0.0× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 11.0× (31.96%)
Jun 2026 16.2× 96.92%
Mar 2026 8.2× (30.64%)
Dec 2025 11.9× (58.07%)
26 more quarters

Against its own ten years

Low 0.0× High 326,375×
Ten-year median 21.1×
Current reading's percentile 30

EV/Sales against peers

Company EV/Sales
TLX Telix Pharmaceuticals Limited compare n/m
MBX MBX Biosciences, Inc. compare n/m
ZLAB Zai Lab Limited Unsponsored ADR compare 4.7×
BEAM Beam Therapeutics Inc. 12.2×
RCUS Arcus Biosciences, Inc. compare 17.5×
XNCR Xencor, Inc. compare 21.6×
IDYA IDEAYA Biosciences, Inc. compare 63.7×
NAMS NewAmsterdam Pharma Company N.V. compare 66.6×
VRDN Viridian Therapeutics, Inc. compare 91.0×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on BEAM